HAB-1: A New Cell Line for Producing Human Monoclonal Antibodies
Author Information
Author(s): G. Faller, H.P. Vollmers, I. Weiglein, A. Marx, C. Zink, M. Pfaff, H.K. Muller-Hermelink
Primary Institution: Institut fur Pathologie, Universitat Wiirzburg
Hypothesis
The study aims to create a genetically stable heteromyeloma for the continuous production of human monoclonal antibodies.
Conclusion
The HAB-1 cell line shows high fusion efficiency and stability for producing human monoclonal antibodies against stomach carcinoma cells.
Supporting Evidence
- HAB-1 cells have a doubling rate of about 25-30 hours.
- The fusion efficiency of HAB-1 is 5-7 times higher than that of other tested cell lines.
- HAB-1 cells do not secrete their own immunoglobulins, making them ideal for fusion with human lymphocytes.
Takeaway
Scientists created a new type of cell that can make human antibodies, which can help in treating diseases like cancer.
Methodology
The study involved creating a heteromyeloma by fusing murine myeloma cells with human lymphocytes and testing for growth and fusion efficiency.
Limitations
The heteromyeloma cells grow slowly and require trypsinization for subculturing.
Participant Demographics
The human lymphocytes were derived from patients with stomach carcinoma.
Want to read the original?
Access the complete publication on the publisher's website